Table of Contents

• Overview of [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL Clinical Research
• Phase 3 Clinical Trial Design
• Target Conditions: Relapsed and Refractory CLL/SLL
• Study Objectives and Endpoints
• Patient Eligibility and Enrollment
• Comparison to Standard Treatment Options

Overview of [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL Clinical Research

[(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL, also known by its investigational name DZD8586, is currently being studied in clinical trials for the treatment of blood cancers^[1]. This investigational drug is being evaluated as a potential therapy for patients whose cancer has not responded adequately to previous treatments or has returned after initial treatment success^[1].

The clinical development program for [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL has progressed to advanced-stage testing, with a Phase 3 trial currently authorized to evaluate its effectiveness in a specific population of cancer patients^[1]. This represents a significant milestone in the drug development process, as Phase 3 trials are typically conducted only after earlier studies have demonstrated promising safety and efficacy results.

The research focus is specifically on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), two closely related blood cancers that affect the lymphatic system^[1]. These conditions are characterized by the abnormal growth and accumulation of white blood cells called lymphocytes. While CLL primarily affects the blood and bone marrow, SLL predominantly involves the lymph nodes, but both are considered different manifestations of the same disease process.

Phase 3 Clinical Trial Design

The clinical trial investigating [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL is classified as a Phase 3 interventional study^[1]. Phase 3 trials represent the final stage of clinical testing before a drug can be submitted for regulatory approval by health authorities such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA). These studies are designed to confirm the drug’s effectiveness, monitor side effects in a larger patient population, and compare the new treatment to existing standard therapies.

The trial has been assigned the identifier 2025-522669-32-00 and has received authorization to proceed^[1]. An interventional study means that participants will actively receive the investigational treatment, and researchers will measure specific health outcomes to evaluate how well the drug works. This is different from observational studies, where researchers simply monitor patients without providing specific interventions.

The study design incorporates a comparative approach, meaning that [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL will be evaluated against investigator’s choice of treatment^[1]. This design allows researchers to determine whether the new drug offers advantages over currently available treatment options. The investigator’s choice arm provides flexibility for doctors to select the most appropriate standard therapy based on each patient’s individual circumstances, medical history, and previous treatments.

Target Conditions: Relapsed and Refractory CLL/SLL

The Phase 3 trial for [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL specifically targets patients with relapsed or refractory (r/r) chronic lymphocytic leukemia and small lymphocytic lymphoma^[1]. Understanding these terms is important for patients and families considering participation in the trial.

Relapsed disease refers to cancer that has returned after a period of improvement or remission following previous treatment. Patients with relapsed CLL or SLL initially responded well to therapy, but the cancer cells eventually began growing again. This can occur months or even years after successful treatment, and it indicates that the previous therapy is no longer effective at controlling the disease.

Refractory disease describes cancer that did not respond adequately to previous treatment from the beginning, or stopped responding during treatment. Patients with refractory CLL or SLL face particular challenges because their disease has demonstrated resistance to standard therapies. These patients have limited treatment options and often need access to new investigational drugs that work through different mechanisms.

Both CLL and SLL are types of slow-growing (indolent) lymphoid cancers that originate from B-lymphocytes, a type of white blood cell that normally helps fight infections. In CLL, the abnormal lymphocytes accumulate primarily in the blood and bone marrow, while in SLL, they predominantly collect in the lymph nodes and other lymphatic tissues. Despite these differences in location, the cancer cells in both conditions have similar characteristics, and the diseases are treated using similar approaches.

Study Objectives and Endpoints

The primary objective of the Phase 3 clinical trial is to evaluate the anti-tumor efficacy of [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL compared to investigator’s choice of treatment^[1]. Anti-tumor efficacy refers to the drug’s ability to fight cancer cells, shrink tumors, and control disease progression. This is the most important measure of whether the new treatment offers meaningful benefits to patients.

In clinical trials for blood cancers like CLL and SLL, anti-tumor efficacy is typically assessed through several key measures:

• Overall response rate: The percentage of patients whose cancer shrinks or disappears after treatment. This includes both complete responses (no detectable cancer) and partial responses (significant tumor shrinkage).
• Progression-free survival: The length of time that patients live without their cancer getting worse. This measures how long the treatment can control disease growth.
• Overall survival: The length of time that patients remain alive after starting treatment. This is considered the most important endpoint in cancer trials.
• Duration of response: How long the cancer remains controlled in patients who respond to treatment. Longer durations indicate more durable treatment effects.
• Quality of life: Patient-reported measures of physical symptoms, emotional well-being, and ability to perform daily activities during treatment.

By comparing [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL to investigator’s choice, the trial aims to determine whether the new drug offers superior anti-tumor activity and potentially better outcomes for patients with relapsed or refractory disease^[1]. The results will help doctors and patients make informed decisions about treatment options if the drug receives regulatory approval.

Patient Eligibility and Enrollment

The Phase 3 trial for [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL plans to enroll approximately 250 patients^[1]. This sample size is carefully calculated to provide sufficient statistical power to detect meaningful differences between the investigational drug and standard treatment options. A larger patient population in Phase 3 trials helps ensure that the results are reliable and can be generalized to the broader patient population.

The trial is specifically designed for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma^[1]. To be eligible for participation, patients must have received previous treatment for their disease that either stopped working or never worked adequately. This ensures that the trial enrolls patients who truly need new treatment options and for whom standard therapies have proven insufficient.

While the specific detailed eligibility criteria are determined by the trial protocol, typical requirements for CLL/SLL trials include:

• Confirmed diagnosis: Patients must have a documented diagnosis of CLL or SLL based on blood tests, bone marrow examination, or lymph node biopsy.
• Prior treatment history: Patients must have received at least one previous line of therapy that was unsuccessful or to which their disease has become resistant.
• Measurable disease: Patients must have disease that can be measured and monitored through blood tests, imaging studies, or physical examination.
• Adequate organ function: Patients typically need to have sufficient liver, kidney, and bone marrow function to safely receive the investigational treatment.
• Performance status: Patients must be well enough to participate in the trial and undergo regular monitoring and assessments.

Patients interested in participating in the trial should discuss their eligibility with their oncologist or hematologist, who can provide information about trial locations and the enrollment process.

Comparison to Standard Treatment Options

A key feature of the Phase 3 trial design is the comparison of [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL to investigator’s choice of treatment^[1]. This comparative approach is essential for determining whether the new drug offers advantages over existing therapies and justifies its potential use in clinical practice.

The investigator’s choice arm allows treating physicians to select from available standard treatment options based on several factors:

• Patient’s treatment history: Which therapies the patient has previously received and how they responded
• Disease characteristics: Specific features of the patient’s cancer, including genetic markers and disease burden
• Patient’s overall health: Other medical conditions, organ function, and ability to tolerate different treatment approaches
• Available approved therapies: Standard treatment options that have demonstrated effectiveness in relapsed or refractory CLL/SLL

For patients with relapsed or refractory CLL and SLL, standard treatment options may include various classes of drugs such as targeted therapies, chemotherapy combinations, and immunotherapy agents. The flexibility of investigator’s choice ensures that patients in the comparison arm receive appropriate, individualized treatment rather than a single fixed regimen that may not be optimal for everyone.

By comparing [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL to this flexible standard of care, the trial will provide valuable information about whether the investigational drug offers improved anti-tumor efficacy, better tolerability, or other advantages that would make it a preferred treatment option^[1]. The results will help guide treatment decisions for future patients with relapsed or refractory disease and may lead to regulatory approval if the drug demonstrates superior benefits.

The authorization status of the trial indicates that regulatory authorities have reviewed the study design and approved it to proceed^[1]. This represents an important step forward in making [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL potentially available to patients who need new treatment options for difficult-to-treat blood cancers.